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1.  Introduction 
1.1  Ischemia and ischemia/reperfusion injury 
 
Organ dysfunctions characterized by ischemia/reperfusion (I/R) are among the leading causes 
of death (1). The term ischemia describes an impaired or interrupted blood supply to tissues 
as a result of reduced or obstructed arterial inflow (2,3). This leads to an insufficient supply of 
the tissue with essential substances such as oxygen and as a result subsequent depletion of 
cellular adenosine triphosphate (ATP) (4). The main therapeutic strategy to reduce ischemic 
injury is the rapid restoration of blood flow (2), in the heart for example by percutaneous 
coronary intervention (PCI) or thrombolysis in patients with acute myocardial infarction (AMI) 
(5). Surprisingly, reoxygenation by restoration of the arterial blood flow can cause an extensive 
inflammatory response and exacerbation of the tissue injury (6). This phenomenon is called 
“reperfusion injury” (6,7). Experimental studies showed, that almost 50% of the final infarct size 
after myocardial infarction is due to the reperfusion injury (7).  
I/R-injury is of high clinical relevance because it contributes to pathologies in various conditions 
(6). Examples are myocardial infarction, stroke, multiple organ I/R-injury due to trauma, or 
organ transplantation as well as other surgical interventions that cause a temporary arrest of 
arterial blood flow (2,6).  
The pathophysiological mechanisms underlying I/R-injury are complex. Anaerobic metabolism 
and lactate accumulation during extended ischemia result in decreased ATP levels and a lower 
intra-cellular pH (1). This leads to impaired ATPase-dependent ion transport mechanisms and 
intra-cellular and mitochondrial calcium (Ca2+) overload as well as cell swelling (1,8). Upon 
reperfusion, reactive oxygen species (ROS) are produced and a pro-inflammatory 
immunoreaction is initiated (8). I/R triggers the opening of the mitochondrial permeability 
transition pore (mPTP) (8). Finally release of the pro apoptotic factor cytochrome C (Cyt C) is 
induced by the mPTP opening and results in cell-death and tissue damage (9). The pro-
inflammatory immunoreaction along with a leukocyte infiltration and activation of the 
complement system leads to a further aggravation of the tissue damage (10,11) (Fig. 1). 
I/R is associated with hypoxia, which is characterized by a reduced partial pressure of oxygen 
in the arterial blood, or reduced oxygen content in a specific tissue or organ (3). In the 
endothelium hypoxia results in a decreased endothelial adenylate cyclase activity and 
decreased intra-cellular cyclic adenosine monophosphate (cAMP) levels (6,12,13). This leads 
to a weakened barrier function of endothelial cells and results in increased vascular 
permeability and vascular leakage (6,12,13).  
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Figure 1: Ischemia/reperfusion-injury and cell death 
Simplified diagram of the pathophysiological mechanisms induced by the ischemia/reperfusion-injury 
(I/R-injury). Based on Kalogeris T et al. (8). 
 
1.2  Organ protective strategies 
 
Due to the high mortality connected to I/R-injuries (1), it is of great clinical interest to establish 
therapeutic strategies to protect organs form I/R-injury. A very promising method to protect 
cells and tissues, but also organs like the heart from I/R-injury is ischemic conditioning (14,15). 
Conditioning refers to a mechanism that enables an organ or tissue to develop adaptation 
processes to cope better with an ischemia (16).  
Depending on the temporal context to the ischemia, conditioning can be divided into pre- and 
postconditioning (16). Protective interventions that occur before the ischemia are referred to 
as preconditioning, protective interventions that occur at the time of reperfusion are referred to 
as postconditioning (16) (Fig. 2). Furthermore, conditioning can be divided according to (i) the 
location where the protective stimulus is applied: Short and possibly repeated ischemia to the 
organ or tissue itself (local pre- and postconditioning), or distal to the organ or tissue (remote 
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pre- and postconditioning) and (ii) the type of intervention which is applied: Ischemia, or 
pharmacological stimuli such as anesthetics and noble gases (16,17). 
Different pharmacological stimuli such as volatile anesthetics (isoflurane, sevoflurane) and 
noble gases (xenon, helium) can protect from the I/R-injury (18–21). The underlying 
mechanisms are very similar to the ones described for ischemic conditioning (17). 
 
  
Figure 2: Organ protective strategies: Pre- and postconditioning 
 
1.2.1  Conditioning with helium 
 
Helium is a colorless, odorless and tasteless monoatomic gas with a lower density than air 
(22). Along with neon, argon, krypton, xenon and the radioactive radon it belongs to the noble 
gases, which have in common that their outer shell of valence electrons is filled (23,24).  
The noble gas helium has been shown to mimic the early and late effects of ischemic 
preconditioning on the human endothelium which makes helium a promising reagent for 
pharmacological conditioning (21).  
In the context of pharmacological conditioning helium is of great interest as helium, in contrast 
to the volatile anesthetics isoflurane and sevoflurane and the noble gas xenon, has no 
anesthetic properties and can therefore also be used in awake patients (22). Helium is called 
a “non-immobilizer”, meaning that it is intrinsically without anesthetic effect (24,25). 
Furthermore no hemodynamic side effects of helium have been described (23), which makes 
helium appealing for the use in patients with cardiovascular risk factors (22). Even though 
helium is called an inert gas, experimental studies in animals and humans have shown that it 
is not biochemically inert and can exert biologic effects (22).  
Recent studies postulated that helium conditioning is able to protect the heart against I/R-injury 
and reduces infarct size (26–36). Preconditioning by three times 5 min of helium inhalation 
before a subsequent ischemia of the heart leads to reduced infarct size in rabbits (26). 
Furthermore helium preconditioning induces mitochondrial uncoupling and reduces infarct size 
in young rats (33). In aged rats, however, this effect is lost (33). Different concentrations of 
helium can protect the heart from I/R-injury (35). 70%, 50% and 30% of helium are potent to 
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induce preconditioning of the rat heart, however, 10% of helium are not potent enough (35). 
Helium can also protect the hypertensive myocardium from I/R-injury (36). However, in 
contrast to normotensive hearts only a combination of pre-, post- and late preconditioning by 
helium has a protective effect in hypertensive hearts (36).  
Beside the protective effect of helium on the heart, animal and in-vitro experiments showed 
that helium also protects the brain from ischemic stroke (37): Various animal and in-vitro 
studies revealed that helium conditioning can reduce cerebral infarct size (37–40) and 
increases the number of viable neurons after a cerebral ischemia (38). Furthermore animal 
studies suggested that helium improves neurological outcomes after cerebral ischemia 
(38,40–42). 
Unfortunately, the large amount of experimental data on helium-induced conditioning has not 
been translated to the clinical situation (23). However, a study by Smit et al. demonstrated in 
healthy volunteers, that helium can protect the human endothelium from I/R-injury by 
mimicking the early and late effect of ischemic preconditioning (21). 
In the human endothelium in-vitro, helium leads to reduced endothelial permeability (43). As 
I/R-injury can cause endothelial dysfunction and reduce endothelial barrier function (6,44), the 
effect of helium on the human endothelial permeability might be one of the underlying 
mechanisms of helium-induced conditioning.  
 
1.3  Target cells for helium conditioning: The endothelium 
 
The endothelium is the first target organ (45,46) to get in contact with circulating blood and the 
respective circulating factors and hypoxic conditions. Therefore, the human endothelium might 
play a key role in helium-mediated organ protection.  
Blood vessels are mainly composed of endothelial cells, pericytes, smooth muscle cells and 
the basal membrane (47). The endothelium lines the inner surface of blood vessels and acts 
as a selective permeable barrier to fluids, solutes and bacteria, separating blood from 
underlying tissue (48–50). Alterations of the endothelial barrier function can cause irregular 
flow of fluids and proteins resulting in tissue edema and dysfunction (51) as well as  
inflammation by bacterial crossing of the barrier (52). Adhesions between the cells as well as 
the actin cytoskeleton are critically involved in regulating endothelial permeability (49,50). 
In a classical way endothelial permeability results from two different routes across the vessel 
wall (51). The first way across the endothelium is trans-cellular, by transcytosis and the second 
way is para-cellular, through the inter-endothelial space (51). However, the para-cellular and 
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the trans-cellular pathways seem to be dependent on each other to maintain tissue fluid 
homeostasis (51).  
Trans-cellular transport or transcytosis is a receptor-mediated transport through the 
endothelial cells. It enables trafficking of macromolecules like albumin, insulin, lipids and 
hormones and is enabled by vesicular transport mechanisms (51,53).  
Para-cellular permeability is maintained mainly by inter-endothelial junctions, which connect 
neighboring endothelial cells into a continuous monolayer (51). Inter-endothelial junctions 
include tight- (TJ), gap- (GJ) and adherens junctions (AJ) (51) (Fig. 3). TJ are composed of 
transmembrane proteins including occludin, claudin and small junctional immunoglobulins  
(54). GJ are formed by two connexons each consisting of six connexin (Cx) molecules (55,56) 
and AJ are formed mainly by vascular endothelial - cadherin (VE-cadherin) (54). AJ and TJ 
promote adhesions of adjacent endothelial cells and maintain the restrictiveness of the 
endothelial barrier, GJ form channels between adjacent cells allowing the exchange of water, 
ions and other small molecules and are able to transmit signals between the cells of the 
endothelial monolayer (51). Under physiological conditions para-cellular transport only allows 
to transport solutes smaller than 3 nm in radius (51,57). Well-functioning AJ are important for 
the regulation of para-cellular permeability and disruption of their VE-cadherin homophilic 
bindings leads to interstitial edema (51).  
Focal adhesions connect the endothelial cells to the basement membrane (58). Caveolin-1 
(Cav-1) is located in caveolae and is involved in vesicular uptake, cell signaling and 
maintaining cholesterol homeostasis (59) (Fig. 3). 
 
  
Figure 3: Endothelial barrier 
Cav-1 = caveolin-1, Cx43 = connexin-43, VE-cadherin = vascular endothelial - cadherin. Molecules 
pictured in red are investigated within this study. 
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1.3.1  Caveolae and Caveolins 
 
Caveolae are lipid enriched invaginations of the plasma membrane (60) and caveolins (Cavs) 
are the structural membrane proteins essential for the formation of caveolae (24,61) (Fig. 3). 
In a traditional way caveolae are mainly responsible for vesicular uptake associated with 
transcytosis, pinocytosis and potocytosis (59). Caveolae contain Cav-1 and traffic 
macromolecules from the luminal side of the endothelium facing the blood flow, to the basal 
surface facing the extra-vascular space (62). However, recent findings revealed, that Cavs are 
also involved in other functions, like the regulation of cell signaling and maintaining cholesterol 
homeostasis (59). 
Cavs were originally named according to their detection in caveolae, but today it is widely 
excepted, that they are also present elsewhere in the cell (63). Cavs, which have a molecular 
weight of 21 - 24 kDa (64), are currently known to consist of three isoforms: Cav-1, Cav-2 and 
Cav-3 (65). The isoforms Cav-1 and Cav-2 are found in various cell types, including endothelial 
cells, whereas Cav-3 is mainly found in striated muscle cells (cardiac and skeletal) and certain 
smooth muscle cells (65).  
Over the last years, evidence was provided, that (i) caveolae and the Cav isoforms 1 and 3 
are critically involved in cardiac protection from myocardial I/R-injury (66). Furthermore, 
evidence was provided, that (ii) stimuli producing preconditioning, including short periods of 
I/R and the exposure to volatile anesthetics as well as the noble gas helium alter the numbers 
of membrane caveolae and the expression rates of Cavs (43,67). 
Cavs anchor signaling molecules and regulate multiple cellular processes such as inter- and 
intra-cellular signal transduction (24,59). Furthermore, Cavs play a key role in anesthetic-
induced organ protection (23,68). Through their scaffolding domain (caveolin scaffolding 
domain (CSD)), Cavs can operate as chaperons and attract different signaling molecules to 
caveolae thereby directly influencing the spatial and temporal regulation of signal transduction 
(66). Signaling molecules bind to the CSD in an inactive state and can then be activated and 
released by conformational changes (63,69).  
Some of the proteins known to interact with the CSD, are also known to be involved in helium-
induced conditioning (24,63). These proteins include the endothelial nitric oxide synthase 
(eNOS), protein kinase A (PKA) and the enzymes of the reperfusion injury salvage kinase 
(RISK) pathway: phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase 
kinase 1 (MEK-1) (24,63,70) (Fig. 4). 
Helium has been shown to induce various biological changes, and membrane proteins like 
Cavs might be important in the helium-induced organ protection (24). Animal and cell culture 
experiments revealed that helium leads to a release of Cavs (especially Cav-1/3) and suggest 
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that Cavs are specifically secreted from endothelial cells into the circulation from where they 
can reach various organs and exert protective effects (43,67). 
 
 
Figure 4: Caveolin scaffolding domain (CSD) 
CSD = caveolin scaffolding domain, eNOS = endothelial nitric oxide synthase, He = helium, MEK1 = 
mitogen-activated protein kinase kinase 1, PI3K = phosphoinositide 3-kinase, PKA = protein kinase A. 
Based on Patel HH et al. (63). 
 
1.3.2  Junctional molecules 
1.3.2.1  Vascular endothelial - Cadherin (VE-cadherin) 
 
VE-cadherin is the main molecule to form AJ by Ca2+-dependent homophilic bindings between 
VE-cadherin molecules of adjacent endothelial cells (54) (Fig. 3). VE-cadherin is found only in 
endothelial cells and is part of the super-family of classical cadherins (47). Within the AJs VE-
cadherin is essential for the endothelial barrier function and regulates the expression and 
spatial distribution of different junctional molecules, among which are N-cadherin and claudin-
5  (47). Primarily b- and p120-catenins bind to the cytosolic tail of VE-cadherin and connect it 
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to the actin cytoskeleton via actin binding proteins such as vinculin, a-catenin and eplin (47). 
Phosphatases and kinases regulate the activity of VE-cadherin adhesions in endothelial cells 
according to extra-cellular stimuli (51). Different receptors at the cell surface of the endothelium 
modulate the stability of VE-cadherin adhesions and organize the actin cytoskeleton in 
response to various stimuli (51). Decreased VE-cadherin levels are correlated with barrier 
disruption and increased permeability (47,71). 
VE-cadherin is involved in conditioning mechanisms (72–74). The volatile anesthetic 
sevoflurane as well as angiopoietin-1 can preserve endothelial barrier function by maintaining 
VE-cadherin levels (72,73). Furthermore, the herbal medicine extract tongxinluo, which is 
known to induce preconditioning, leads to an upregulation of VE-cadherin in the endothelium 
(74). 
 
1.3.2.2  Connexin-43 (Cx43) 
 
Cxs are the protein family that forms GJ between cells and enables inter-cellular 
communication between endothelial cells, as well as cardiomyocytes (75). This cell-cell 
communication regulates vascular tone, endothelial function, metabolic interchange and 
preserves cardiac rhythm (75,76). GJ are formed by two facing hemichannels or connexons, 
each of the communicating cells contributing one of them (55,56). Every connexon is formed 
by six Cx molecules (56) (Fig. 3). GJ allow the inter-cellular exchange of molecules with a 
molecular weight of less than 1.5 kDa, such as signaling molecules as Ca2+ and inositol 
trisphosphate (IP3) (55). The nomenclature of Cxs is based on their molecular weight (55). 
Cx43 therefore refers to the Cx with a molecular weight of 43 kDa (55).  
Cx43 resides both in the plasma membrane, where its main function is the inter-cellular 
communication through GJ (75) and in the mitochondria, where it regulates mitochondrial 
physiology and myocyte apoptosis (75,77).  
Ischemic preconditioning leads to a preserved sarcolemmal Cx43 activity during sustained 
ischemia, and protects the cell by attenuating cellular edema (78). Furthermore ischemic 
preconditioning translocates Cx43 to the mitochondria, where it increases ATP formation and 
contributes to the release of ROS, which are two important mechanisms of conditioning (78). 
Interestingly, in addition to the proteins already known to be involved in helium-induced 
conditioning, also Cx43 interacts with the scaffolding domain of Cav-1 (CSD) and additionally 
interacts with the C-terminal domain of Cav-1 (79). 
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1.3.3  Caveolins and junctional molecules in conditioning 
 
Cavs as well as the junctional molecules VE-cadherin and Cx43 are involved in various 
conditioning mechanisms (24,72,74,78).  
In 2001 Young et al. demonstrated in isolated rat hearts that infusion of the CSD peptide of 
Cav-1 into ischemia/reperfused hearts increases the recovery of the cardiac function (80). A 
study in rats in-vivo showed that I/R of the myocardium down-regulates the Cav-1 levels in 
ischemic as well as non-ischemic zones of the myocardium (81). Isoflurane is known to induce 
pharmacological conditioning of the heart and Patel et al. demonstrated in 2007 that a Cav-1 
knock-down abolishes the isoflurane-induced infarct size reduction, indicating that conditioning 
by isoflurane is dependent on Cav-1 (82). In addition to Cav-1, Cav-3 is also involved in 
pharmacological conditioning by isoflurane. Preconditioning by isoflurane reduces infarct size 
and cardiac troponin levels in mice hearts after I/R (68). A Cav-3 knock-out in mice abolishes 
this isoflurane-induced cardiac protection, indicating that conditioning by isoflurane is also 
dependent on Cav-3 (68). Furthermore, Cav-1 plays a role in pharmacological conditioning by 
helium. After helium inhalation decreased levels of Cav-1/3 were found in mice hearts and 
increased levels were found in the serum of mice (67). A following study in rats partly supported 
these findings by demonstrating that helium postconditiong increases Cav-3 in the serum of 
rats (83). The same study, furthermore, revealed that helium postconditioning increases the 
amounts of Cav-1/3 in the membrane fraction of ischemic cardiac tissue in rats (83). Jiang et 
al. demonstrated the relationship between Cav-1 and endothelial permeability in a 
preeclampsia study employing hypoxic trophoblast conditioned medium (84). This medium 
increases endothelial permeability and Cav-1 levels in endothelial cells (84). However, a Cav-
1 knock-out abrogates the effect on the endothelial permeability (84). This indicates that Cav-
1 is a main part of the pathway that regulates endothelial monolayer permeability (84). 
Overexpression of Cav-1 in mice leads to endogenous cardiac protection similar to wild-type 
mice undergoing ischemic conditioning, confirming the key role of Cav-1 in ischemic 
conditioning (85). In 2015 Hamaguchi et al. confirmed the role of Cavs in isoflurane-induced 
preconditioning in mice by demonstrating that conditioning by isoflurane increases Cav-3 in 
the heart after infarct induction and is abolished in Cav-3 knock-out mice (86). 
VE-cadherin is involved in pharmacological conditioning by angiopoietin-1 (73). Lee et al. 
showed that angiopoietin-1 prevents vascular leakage through a regulation of VE-cadherin 
phosphorylation (73). Sevoflurane-induced preconditioning preserves endothelial barrier 
function and maintains VE-cadherin levels by preventing VE-cadherin internalization (72). This 
demonstrates the key role of VE-cadherin in this conditioning strategy. The herbal medicine 
extract tongxinluo leads to an upregulation of VE-cadherin, which might be one of the key 
targets of pharmacological conditioning by tongxinluo (74).  
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The role of Cx43 in ischemic conditioning was postulated in various publications. Infarct size 
reduction induced by ischemic conditioning in mice is abrogated in Cx43 deficient mice, 
pointing towards a key role of Cx43 in ischemic conditioning (87). Schulz et al. showed that 
ischemic conditioning induces Cx43 phosphorylation during ischemia in pic hearts in-vivo (88). 
This Cx43 phosphorylation induced by ischemic conditioning was confirmed in isolated buffer-
perfused rabbit hearts and in addition a reduction in infarct size was found (89). In isolated rat 
hearts ischemic conditioning enhances the mitochondrial localization of Cx43 (90). Rodriguez-
Sonovas et al. demonstrated that ischemic conditioning transports Cx43 to the inner 
mitochondrial membrane and furthermore, revealed that normal mitochondrial Cx43 content is 
crucial for cardioprotection by ischemic conditioning (91). The involvement of Cx43 in ischemic 
conditioning of the heart was, furthermore, supported by findings in aged mice hearts (92). Left 
ventricular content of Cx43 is reduced in hearts of aged animals and in addition, the effect of 
ischemic preconditioning on infarct size reduction is abolished in these hearts (92). This led to 
the conclusion that the reduced Cx43 levels might be responsible for the age related loss of 
ischemic preconditioning, once more demonstrating the involvement of Cx43 in ischemic 
conditioning (92). 
Table 1 gives an overview of Cav-1/3, VE-cadherin and Cx43 in different conditioning 
strategies. 
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Molecule Coditioning 
strategy 
Mechanism of regulation/ action Reference 
Cav-1 Pharmacological: 
CSD peptide of  
Cav-1 
Infusion of CSD peptide of Cav-1 into 
ischemic/reperfused hearts increases 
recovery of cardiac function 
Young LH,  
2001 (80) 
Cav-1 Ischemic I/R-injury down-regulates Cav-1 Ballard-Croft C,  
2006 (81) 
Cav-1 Pharmacological: 
isoflurane 
Cav-1 knock-out abolishes isoflurane-
induced infarct size reduction 
Patel HH,  
2007 (82) 
Cav-1/3 Pharmacological: 
helium 
Conditioning with helium leads to 
decreased level of Cav-1/3 in the mice 
hearts and increased levels in the 
serum of mice 
Weber NC,  
2013 (67) 
Cav-1 Ischemic Hypoxic trophoblast conditioned 
medium increases endothelial 
permeability and Cav-1 levels in 
endothelial cells, this effect is abrogated 
by a Cav-1 knock-down 
Jiang R,  
2014 (84) 
Cav-1/3 Pharmacological: 
helium 
Helium postconditioning regulates Cav-
1/3 levels in cardiac tissue of rats and 
increases Cav-3 in the serum of rats 
Flick M,  
2016 (83) 
Cav-3 Pharmacological: 
isoflurane 
Cav-3 knock-out abolishes isoflurane-
induced reduction of infarct size and 
cardiac troponin levels 
Horikawa YT,  
2008 (68) 
 
Cav-3 Ischemic Endogenous cardiac protection in Cav-3 
overexpressed mice is similar to wild-
type mice undergoing ischemic 
conditioning 
Tsutsumi YM,  
2008 (85) 
Cav-3 Pharmacological: 
isoflurane 
Isoflurane-induced preconditioning 
increases Cav-3 in the heart and is 
abolished in Cav-3 knock-out mice 
Hamaguchi E,  
2015 (86) 
VE-
cadherin 
Pharmacological: 
angiopoietin-1 
Angiopoietin-1 prevents vascular 
leakage through a regulation of  
VE-cadherin phosphorylation 
Lee SW, 
2011 (73) 
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VE-
cadherin 
Pharmacological: 
sevoflurane 
Sevoflurane-induced preconditioning 
preserves endothelial barrier functions 
by maintaining VE-cadherin levels 
Huang Y,  
2015 (72) 
VE-
cadherin 
Pharmacological: 
tongxinluo 
Herbal medicine extract tongxinluo 
leads to an upregulation of  
VE-cadherin and protects against 
myocardial I/R-injury 
Qi K,  
2015 (74) 
Cx43 Ischemic Cx43 knock-out abrogates effect of 
ischemic conditioning in mice 
Schwanke U,  
2002 (87) 
Cx43 Ischemic Ischemic conditioning preserves Cx43 
phosphorylation during ischemia in pig 
hearts in-vivo 
Schulz R,  
2003 (88) 
Cx43 Ischemic Ischemic conditioning induces Cx43 
phosphorylation and reduces infarct 
size in isolated buffer perfused rabbit 
hearts 
Miura T,  
2004 (89) 
Cx43 Ischemic Ischemic conditioning enhances 
mitochondrial localization of Cx43 in 
isolated rat hearts 
Boengler K,  
2005 (90) 
Cx43 Ischemic Ischemic conditioning transports Cx43 
to the inner mitochondrial membrane 
and normal mitochondrial Cx43 content 
is important for cardioprotection 
Rodriguez-
Sinovas A,  
2006 (91) 
Cx43 Ischemic Cardioprotection by ischemic 
conditioning is lost in aged mice hearts, 
possibly due to reduced left ventricular 
Cx43 content in the aged heart 
Boengler K,  
2007 (92) 
Table 1: Caveolins and junctional molecules in conditioning 
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1.4  Aim of the study 
 
The noble gas helium has been shown to mimic the early and late effects of ischemic 
preconditioning on the human endothelium which makes helium a promising reagent for organ 
protective strategies. Recent studies suggested that helium decreases protein levels of 
caveolin-1 (Cav-1) in the human endothelium and attenuates the permeability of human 
umbilical vein endothelial cell (HUVEC) monolayers. However, the underlying cellular and 
molecular mechanisms and the precise role of Cav-1 in helium-mediated regulation of 
endothelial barrier integrity are still unclear. 
 
The aim of this study was to gain deeper insight into the mechanisms responsible for the barrier 
protective functions of helium. Therefore, employing in-vitro cultured primary HUVEC and 
small interfering RNA (siRNA) transfection experiments, we investigated (i) whether Cav-1 is 
involved in helium-mediated stabilization of the endothelial barrier and (ii) whether the 
expression of the key junctional molecules vascular endothelial - cadherin (VE-cadherin) and 
connexin-43 (Cx43) is regulated by helium and might be involved in the effects of helium on 
the endothelial barrier function. 
 
The results of this study will lead to a better understanding of the cellular and molecular 
mechanisms behind the barrier protective effects of helium and in combination with further 
translational trials could help to implement helium into organ protective strategies in humans. 
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2.  Material and Methods 
2.1  Material  
 
A detailed list of manufacturers is included in the appendix section (7.1 List of manufacturers). 
 
2.1.1  Cell culture 
 
Devices 
Capnomac Ultima (Datex), Centrifuge 5810 R, Rotor A-4-81, Radius 18.0 (Eppendorf), Clean 
Air, Biological safety cabinet, class II (Telstar Laboratory Equipment), Heracell 150 I CO2 
incubator (Thermo Scientific), Leica DM-RA(X) Microscope (Leica Microsystems), Microplate 
fluorescence reader FLx800 (BioTek). 
 
Consumables 
12-well-plate transwell inserts, pore diameter size: 0.4 µm (Corning Costar), 6-well- and 12-
well-plates (Greiner Bio One), Cell culture flasks 25 cm2 and 75 cm2 (Corning), Cell scrapers 
(Corning Life sciences), OptiPlate 96 Black (Packard BioScience). 
 
Chemicals 
Amphotericin B (Sigma-Aldrich), calcium chloride (MERCK Millipore), collagenase A (Roche), 
ECGM (Promocell), ECGM supplement mix (Promocell), fetal bovine serum (PAA), FITC-BSA 
(Sigma-Aldrich), gas mixture: 5% CO2, 25% O2, 70% He (Linde Gas Benelux), gas mixture: 
5% CO2, 25% O2, 70% N2 (Linde Gas Benelux), gelatine (BD Diagnostic system), KH2PO4 
(Merck), L-glutamine (Sigma-Aldrich), lipofectamine RNAiMAX (Invitrogen), medium 199 
(PAN), milliQ-water made by Milli-Q Synthesis: Ultrapure Water, System, type 1 (MERCK 
Millipore), Na2HPO4 (Sigma-Aldrich), NaCl (Merck), penicillin-streptomycin (Sigma-Aldrich), 
silencer negative control siRNA #1 (Ambion), siRNA Cav-1 (Ambion), Triton X-100 (Sigma-
Aldrich), trypsin-EDTA (Invitrogen). 
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Buffer solutions and cell culture medium 
 
B1 10x PBS 437.5 g NaCl, 
71.1 g Na2HPO4 x 2H2O, 
10.5 g KH2PO4,  
add 5 l milliQ-water, pH 7.4 
B2 PBS+ 100 ml 10x PBS (B1), 
900 ml milliQ-water, 
100 mg MgCl2,  
100 mg CaCl2 
B3 Umbilical cord buffer 500 ml PBS+ (B2),  
5 ml penicillin-streptomycin,  
5 ml amphotericin B 
M1 Stop medium 428 ml medium 199 (M199),  
50 ml fetal bovine serum (FBS),  
5 ml penicillin-streptomycin,  
5 ml amphotericin B,  
5 ml L-glutamine 
M2 Cell culture medium with 
antibiotics and antimycotics 
428 ml endothelial cell grows medium (ECGM),  
50 ml FBS,  
5 ml penicillin-streptomycin,  
5 ml amphotericin B,  
12.2 ml of ECGM supplement mix 
M3 Starving medium 96 ml ECGM,  
2 ml FBS,  
1 ml penicillin-streptomycin,  
1 ml amphotericin B 
M4 Cell culture medium without 
antibiotics and antimycotics 
87.6 ml ECGM,  
10 ml FBS,  
2.4 ml of ECGM supplement mix 
M5 Stop medium without 
antibiotics and antimycotics 
89 ml M199,  
10 ml FBS,  
1 ml L-glutamine 
Table 2: Buffer solutions and cell culture medium used for cell culture 
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SiRNA, transfection reagents and controls 
 
Name Description Company 
Lipofectamine RNAiMAX Transfection reagent Invitrogen 
Silencer 
Negative Control siRNA #1 
Cat#: AM4611 
Negative control siRNA Ambion 
Cav-1 (sense)  
5’CCCUAAACACCUCAACGAU(dT)(dT)3’ 
Cav-1 (antisense)  
5’AUCGUUGAGGUGUUUAGGG(dT)(dT)3’ 
SiRNA Cav-1 
 
Sigma-Aldrich 
Table 3: SiRNA, transfection reagents and controls used for HUVEC transfection 
 
2.1.2  Protein biochemistry 
 
Devices 
Centrifuge 5430R (Eppendorf), Criterion Blotter Gel Holder Cassette (Bio-Rad), Criterion cell 
(Bio-Rad), Criterion Blotter (Bio-Rad), Heaterblock III (MFG by Henry Troemner), Odyssey CLx 
imaging system (LI-COR Biosciences), microplate fluorescence reader FLx800 (BioTek). 
 
Consumables 
96-well-plates (Fisher Scientific), Criterion XT precast gel (Bio-Rad), filter paper (Bio-Rad), 
Immobilon FL (MERCK Millipore). 
 
Chemicals 
Aprotinin (Sigma-Aldrich), bromophenol blue (Merck), bovine serum albumin (BSA) (PAA), 
C2H6OS (Sigma-Aldrich), CuSO4 x H2O (Merck), deoxycholate (Sigma-Aldrich), DTT (Sigma-
Aldrich), EDTA (Sigma-Aldrich), Folin & Ciocalteu’s phenol reagent (Sigma-Aldrich), glycerol 
(Sigma-Aldrich), glycine (Appli-Chem), KNa-tartrate (Merck), leupeptin (Sigma-Aldrich), MOPS 
(Sigma-Aldrich), Na2CO3 (Merck), Na3VO4 (Sigma-Aldrich), NaOH (Merck), nonidet P40 
(Sigma-Aldrich), Odyssey blocking buffer (LI-COR Biosciences), pepstatin A (Sigma-Aldrich), 
PMSF (Sigma-Aldrich), precision plus protein all blue standards (Bio-Rad), SDS (Sigma-
Aldrich), Sigma 7-9 (Sigma-Aldrich), SPTB (Sigma-Aldrich), Tris-HCl (Sigma-Aldrich), Trizma 
base (Sigma-Aldrich), Tween-20 (Sigma-Aldrich). 
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Antibodies used for western blot analyses 
 
Primary antibodies 
Target protein MW (kDa) Species Dilution Company 
VE-cadherin 130-140 Rabbit 1:1000 Cell Signaling 
Technology 
Cx43 39-44 Rabbit 1:1000 Cell Signaling 
Technology 
Cav-1 22 Rabbit 1:10000 Abcam 
GAPDH 
(loading control) 
40 Rabbit 1:5000 Abcam 
Alpha-tubulin 
(loading control) 
50 Mouse 1:10000 Sigma-Aldrich 
Secondary antibodies 
Name Species Dilution Company 
Goat anti-rabbit (GAR) - red Goat 1:5000 LI-COR Biosciences 
Goat anti-rabbit (GAR) - green Goat 1:5000 LI-COR Biosciences 
Goat anti-mouse (GAM) - green Goat 1:5000 LI-COR Biosciences 
Table 4: Antibodies for western blot analyses 
 
Inase-inhibitor-mix 
 
Inase-inhibitor-mix 1 mg aprotinin, 
1 mg leupeptin, 
1 mg pepstatin A, 
10 ml Tris-HCl solution, adjust to pH 7.4 
Table 5: Composition of Inase-inhibitor-mix 
 
Buffer solutions 
 
B4 RIPA-buffer 219 mg NaCl, 
197 mg Tris-HCl, 
250 mg nonidet P40, 
62.5 mg deoxycholate, 
25 mg SDS, 
add 25 ml milliQ-water 
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B5 Lysis-RIPA-
buffer 
2500 µl RIPA-buffer (B4),  
25 µl PMSF 100 mM,  
50 µl Na3VO4 100 mM,  
200 µl inase-inhibitor-mix,  
25 µl DTT 100 mM,  
25 µl SPTB 100 mM  
B6 Sample buffer 1 g SDS, 
25 mg bromophenol blue, 
150 mg Trizma base, 
dissolve in 4 ml milliQ-water, 
add 5 ml glycerol and heat to 50oC, adjust pH to 6.8, 
add 1 ml C2H6OS 
B7 10x MOPS-
running buffer 
60.6 g Sigma 7-9, 
104.6 g MOPS, 
10 g SDS, 
3 g EDTA, 
add 1000 ml milliQ-water 
B8 10x transfer 
buffer 
30 g Sigma 7-9, 
144 g glycine, 
add 1000 ml milliQ-water 
B9 1x transfer 
buffer 
200 ml 10x transfer buffer (B8),  
400 ml methanol, 
add 1400 ml milliQ-water 
B10 Blocking buffer Purchased ready for use (Odyssey blocking buffer by LI-COR 
Biosciences) 
B11 Antibody buffer 
solution 
15 ml blocking buffer (B10), 
150 µl Tween-20 (10%, diluted in milliQ-water) 
B12 PBS-T 1000 ml 1x PBS+ (B2), 
2 ml Tween-20 
Table 6: Buffer solutions used for protein biochemistry 
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Reagents for Lowry protein determination 
 
Solution 1 (Lowry reagent A:B:C in relation 100:1:1) 
Lowry reagent A 10 g Na2CO3,  
500 ml 0.1 M NaOH 
Lowry reagent B 2 g KNaC4H4O6 x 4H2O,  
100 ml milliQ-water 
Lowry reagent C 1 g CuSO4 x 5H2O 
100 ml milliQ-water 
Table 7: Composition of Lowry solution 1 
 
Solution 2 (relation 1:1) 
Folin & Ciocalteu’s phenol reagent (purchased ready for use) 
milliQ-water 
Table 8: Composition of Lowry solution 2 
 
2.2  Methods 
2.2.1  Cell culture 
2.2.1.1  Background 
 
As a model for the human endothelium, human umbilical vein endothelial cells (HUVEC) were 
used. HUVEC were freshly isolated from umbilical cords and used for experiments in passages 
three to five. The use of HUVEC was approved by the ethical committee at the Academic 
Medical Center (AMC) in Amsterdam (Waiver: W12_167# 12.17.0196, Ethical Committee 
AMC, Amsterdam). Working with HUVEC took place in a biological safety cabinet (Clean Air, 
biological safety cabinet, class II). 
 
2.2.1.2  HUVEC isolation 
 
HUVEC were isolated from fresh human umbilical cords. Umbilical cords were collected from 
the maternity department of the AMC in Amsterdam. Prior to HUVEC isolation umbilical cords 
were kept in B3 for up to two days at room temperature (RT).  
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Human umbilical cords physiologically have two umbilical arteries and one umbilical vein. The 
umbilical vein can visually be detected by its larger lumen and its thinner wall compared to the 
umbilical arteries. The umbilical vein was cannulated with a vascular irrigation cannula of a 
well-fitting size and fixated using two cable ties on each side. To clean the umbilical vein from 
remaining blood the lumen of the vein was rinsed with B2. Afterwards, tree-way-valves were 
connected to the vascular irrigation cannulas. For digestion of the umbilical cords 0.1 g/l 
collagenase A was injected into the umbilical vein and the umbilical cord was incubated at 
37oC for 25 min in a CO2 incubator (Heracell 150 I CO2 incubator). After incubation, the 
enzymatic reaction of collagenase A was stopped by draining the solution inside the umbilical 
vein into M1. To separate cells from stop medium, the solution was centrifuged at 1100 rpm, 
4°C, for 10 min (Centrifuge 5810 R, Rotor A-4-81, Radius 18.0). The supernatant was 
discarded and the pellet was resuspended in M2.  
HUVEC from two to three different donors were pooled to reduce the effect of interindividual 
differences on the outcome of experiments and to obtain sufficient amounts of cells. 5 ml of 
cells diluted in cell culture medium was pipetted into a cell culture flask with a surface area of 
25 cm2. The cell culture flasks were coated with gelatine for 20 min prior to this step.  
 
2.2.1.3  HUVEC cultivation 
 
Before cells reached confluency the cell culture medium (M2) was changed every two to three 
days, the old cell culture medium was discarded, cells were washed three times with B2 and 
5 ml of fresh cell culture medium (M2) was added. By the time the primary cell cultures had 
reached confluency in 25 cm2 flasks they were passaged to a surface area of 75 cm2 (splitting 
1:3). By the time the cells had reached confluency in 75 cm2 flasks they were passaged again 
into three cell culture flasks with a surface area of 75 cm2 each (splitting 1:3). This procedure 
was repeated until passage two to four for transfection experiments and until passage three to 
five for experiments with non-transfected HUVEC.  
For passaging HUVEC, the medium was discarded and cells were washed three times with 
B2. A trypsin-EDTA solution was heated to 37oC in a water bath and added to the cells (1 ml 
for 25 cm2, 3 ml for 75 cm2, 0.6 ml for one well in 6-well-plates). HUVEC were incubated with 
trypsin-EDTA solution for 1.5 min at 37oC in a CO2 incubator (Heracell 150 I CO2 incubator). 
Cells were detached by gently tapping the cell culture flasks onto the work bench. The reaction 
was stopped by pipetting the cells suspended in a trypsine-EDTA solution into M1. To separate 
cells from cell culture medium the solution was centrifuged at 1100 rpm, 4°C, for 10 min 
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(Centrifuge 5810 R, Rotor A-4-81, Radius 18.0). The supernatant was discarded and the pellet 
was resuspended in fresh M2. 
 
2.2.2  SiRNA transfection 
2.2.2.1  Background 
 
In order to obtain a Cav-1 knock-down model of the human endothelium, small interfering RNA 
(siRNA) was introduced into HUVEC. SiRNA consists of double stranded RNA molecules (93) 
and allows to block the synthesis of a specific protein (94). SiRNA interferes with messenger 
RNA (mRNA), leads to a degradation of the mRNA and results in posttranscriptional gene 
silencing (PTGS) (94). The application of siRNA to knock-down protein levels of Cav-1 in 
HUVEC is well described in the literature (84,95–101). 
 
2.2.2.2  Transfection with Cav-1 siRNA 
 
The experimental protocol used for Cav-1 siRNA transfection in HUVEC is outlined in Fig. 5. 
This protocol was developed based on a protocol from Dr. Zhenlong Chen, University of Illinois, 
Chicago, USA and was modified based on the results of pilot experiments performed in our 
laboratory. In the following protocol, all amounts refer to one well of a 6-well-plate (surface 
area 9.6 cm2). 
 
Day -1: Passage HUVEC into 6-well-plates 
48 hours prior to transfection with siRNA, HUVEC in passages one to three were seeded into 
gelatine coated 6-well-plates containing 3 ml of M2 per well.  
 
Day 0: Starving 
20 hours prior to transfection with siRNA, cells in passages two to four were washed three 
times with B2 and M3 was added to each well (Fig. 5). 
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Figure 5: Transfection with Cav-1 siRNA 
C = well containing negative control siRNA transfected HUVEC, HUVEC = human umbilical vein 
endothelial cells, S = well containing HUVEC starved with M3, T = well containing Cav-1 siRNA 
transfected HUVEC. For medium composition see table 2. 
 
Day 1: Transfection 
HUVEC were transfected at a confluency of 50-80% with siRNA for Cav-1 or scrambled siRNA 
as negative control with the use of lipofectamine RNAiMAX. Immediately before adding the 
siRNA for Cav-1 or negative control siRNA M3 was discarded, the cells were washed three 
times with B2 and 800 µl M4 was added. Four vials (a, b, c and d) were prepared according to 
Fig. 6A. All vials were gently vortexed and kept at RT for 5 min (Fig. 6B). Then the solution in 
vial b was added to the solution in vial a and the solution in vial d was added to the solution in 
vial c and the remaining vials a and c were vortexed gently for 3 seconds (Fig. 6C). The 
resulting solutions were kept at RT for 25 min before they were added onto the cultured cells 
(Fig. 6D,E). This resulted in a final concentration of 100 nM Cav-1 siRNA or negative control 
siRNA on the cultured cells. Throughout the next 6 hours the 6-well-plates were gently shaken 
by hand every 2 hours to allow the siRNA to spread evenly. 6 hours after adding the siRNA for 
Cav-1 or negative control siRNA to the cells, 2 ml of M4 were added to each well. 
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Figure 6: Preparation of siRNA 
C = well containing negative control scrambled siRNA transfected HUVEC, Cav-1 = caveolin-1, ECGM 
= endothelial cell grows medium, RT = room temperature, siRNA = small interfering RNA, T = well 
containing Cav-1 siRNA transfected HUVEC. For medium composition see table 2. 
 
Day 2: Passage of transfected HUVEC 
24 hours after adding siRNA for Cav-1 or negative control siRNA to each well, the cells were 
split 1:2. Cells were either split into gelatine-coated 6-well-plates for western blot analysis or 
onto transwell membranes to perform permeability assays. During Day 1 and Day 2 of the 
transfection protocol no antibiotics or antimycotics were added to the cell culture medium (M4, 
M5). 
 
Day 3: Medium change 
48 hours after adding siRNA for Cav-1 or negative control siRNA to each well, the cells were 
washed three time with B2 and fresh M2 was added to each well (Fig. 5). 
 
Day 4: Western blot analysis or helium/control gas experiment 
After 72 hours the cells were lysed to determine protein knock-down by western blot analysis 
or helium/control gas experiments were started (Fig. 5).  
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2.2.3  Helium and control gas treatment 
 
Cav-1 siRNA transfected and non-transfected HUVEC were grown on gelatine coated 6-well-
plates for western blot analysis of the junctional molecules VE-cadherin and Cx43, or on 
transwell membranes for permeability assays. Before treatment with helium or control gas, the 
cells were washed three times with B2 and fresh M2 was added. Confluent monolayers of Cav-
1 siRNA transfected and non-transfected HUVEC were treated with either 20 min of helium 
(5% CO2, 25% O2, 70% He) or control gas (5% CO2, 25% O2, 70% N2) in a specially designed 
gas chamber (Fig. 7).  The gas flow was set to 5 l/min and outlet gas concentrations were 
monitored by a gas analyzer (Capnomac Ultima). The gas temperature inside the gas chamber 
was kept at 37oC and was constantly monitored. After 20 min of treatment, the cells in 6-well-
plates or permeability membranes were placed into a CO2 incubator (Heracell 150 I CO2 
incubator) at 37oC for 6, 12, or 24 hours. At these time points the cells and supernatants were 
collected for western blot analysis or permeability measurements. If necessary, samples were 
frozen at -80oC. 
 
  
Figure 7: Helium experiments 
Cav-1 = caveolin-1, HUVEC = human umbilical vein endothelial cells, siRNA = small interfering RNA. 
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2.2.4  Western blot analysis 
2.2.4.1  Background 
 
Western blotting is a technique to separate and identify proteins in a sample. During the first 
step, which is called gel electrophoresis, proteins are separated according to their molecular 
weight. In the following step proteins are transferred to a membrane and unspecific binding 
sides of the membrane are blocked with a blocking buffer. A primary antibody binds specifically 
to the protein of interest, a secondary fluorescence-coupled antibody binds to the Fc part of 
this primary antibody and can be detected by its fluorescent signal. Data produced with this 
technique are semi-quantitative as they compare relative protein levels and do not measure 
an absolute quantity of the amount of a protein (102).  
 
2.2.4.2  Western blot implementation 
 
Sample preparation 
At each time point (72 hours after transfection to determine transfection efficiency and 6, 12, 
or 24 hours after exposure to helium/control gas to measure expression of junctional molecules 
VE-cadherin and Cx43), the cell lysates and cell culture media were collected. HUVEC growing 
on 6-well-plates were washed three times with ice-cold B2. 400 µl of ice-cold B5 was pipetted 
into each well and the cells were detached with cell-scrapers. The cell lysate was centrifuged 
at 14000 rpm and 4oC for 10 min (Centrifuge 5430 R) and was collected and stored at -80oC 
until further analyses.  
 
Lowry protein determination  
The Lowry protein assay works through the formation of color complexes that react 
proportionally to the amount of protein in a sample (103).  
Prior to the Lowry protein determination all samples were thawed and diluted (1:20) with milliQ-
water. The required amount of solution 1 was calculated and prepared. 500 µl of solution 1 
for every sample and every standard of the calibration curve were needed. A standard curve 
was prepared by diluting BSA in milliQ-water, this standard was used as a reference for all 
samples. 500 µl of solution 1 was added to 100 µl of each diluted sample and each of the 
standards, followed by an incubation time of 10 min at RT. During this first step, copper ions 
in alkaline solution react with proteins to form complexes (103). In the following step solution 
2 was prepared and 50 µl of solution 2 was added to all samples and standards. After a 
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second incubation time of 30 min at RT the samples and standards were transferred in 
duplicates to a 96-well-plate. The protein concentration was detected colorimetrically at an 
absorbance wavelength of 750 nm using the microplate fluorescence reader FLx800. 
 
Sample dilution 
For western blot analyses, all samples were diluted with B4 to obtain equal protein 
concentrations for related experiments. 
 
Electrophoresis 
Samples were diluted 1:5 with B6. Subsequently, samples were heated at 95oC for 5 min 
(Heaterblock III) to denaturate proteins (102).  
Commercially available gels (Criterion XT precast gel) were used for electrophoresis. B7 was 
diluted 1:10 with milliQ-water and 500 ml per gel were filled into the criterion cell tank. After 
removing the combs 15 µl of the diluted samples were loaded into each pocket of the gel. 
Additionally, 2 µl of a protein marker (precision plus protein all blue standards) was loaded 
onto the gel to function as a reference for the molecular weight.  
The electrophoresis leads to a separation of proteins according to their molecular weight and 
takes around 1 hour and 15 min with a voltage of 150 V. During electrophoresis, the negatively 
charged proteins migrate through the gel. Large molecules migrate slower and small molecules 
faster, which leads to the formation of the protein bands by a separation of the molecules along 
the gel. Bromophenol blue in B6 allows to visualize how far the separation has marched (102). 
 
Protein transfer and blocking 
Prior to the transfer, the membranes (Immobilon FL) were cut to the size of the gels and soaked 
in methanol for 5 min. Fiber pads and filter paper were soaked in cold B9. After electrophoresis 
was complete, the transfer cassette (Criterion Blotter Gel Holder Cassette) was loaded from 
cathode to anode as follows: fiber pad, two filter papers, gel, membrane, two filter papers, fiber 
pad (Fig. 8). One or two transfer cassettes together with an ice block and a magnetic stirrer 
were placed in a transfer tank (Criterion Blotter) and the tank was filled with cold B9. During 
the transfer the magnetic stirrer was constantly rotating, the protein transfer from the gel to the 
membrane took 30 min at a voltage of 100 V. Placing the membrane between the gel and the 
anode leads to a migration of the negatively charged proteins from the gel to the membrane 
(102). After the transfer the gel was discarded and the membrane was blocked in B10 for one 
hour on a shaker. 
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Figure 8: Assembly of gel and membrane for western blot transfer 
 
Protein detection 
After blocking the membranes, they were incubated with the primary antibody in 15 ml of B11 
at 4oC overnight. This step allows the primary antibody to bind specifically to the protein of 
interest. The following primary antibodies were used: alpha-tubulin (1:10000), Cav-1 
(1:10000), Cx43 (1:1000), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:5000), 
VE-cadherin (1:1000) (table 4). The following day the membranes were washed three times 
for 5 minutes with cold B12. Washing removes unspecifically bound antibodies and excessive 
antibodies from the membrane and minimizes the background (102). After the third wash the 
membranes were incubated with a secondary antibody for 1 hour at RT in 15 ml of B11. This 
step leads to a specific binding of the secondary antibody to the Fc part of the primary antibody. 
On membranes with rabbit primary antibodies, anti-rabbit secondary antibodies were used and 
on membranes with mouse primary antibodies, anti-mouse secondary antibodies were used. 
For the primary antibodies binding to the proteins Cav-1, Cx43 and VE-cadherin a secondary 
antibody with a red fluorescent signal was employed; for the loading controls alpha-tubulin and 
GAPDH a secondary antibody with a green fluorescent signal was used. After washing three 
times with cold B12 for 5 minutes, membranes were scanned with the Odyssey CLx imaging 
system.   
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Signal quantification 
Quantification of the signals was performed with Odyssey Imaging Studio software (LI-COR 
Biosciences, Bad Homburg, Germany). The results show the relation of VE-cadherin and Cav-
1 to GAPDH. Because the molecular weights of Cx43 (39-44 kDa) and GAPDH (40 kDa) are 
close together, alpha-tubulin (50 kDa) was used as a loading control for Cx43. 
 
2.2.5  Permeability assays 
 
The permeability of confluent HUVEC monolayers was evaluated by employing fluorescein 
isothiocyanate labelled bovine serum albumin (FITC-BSA) flow through in combination with a 
microporous membrane (Fig. 9). Upon confluency, cells growing on microporous membranes 
with a pore diameter size of 0.4 µm and a area of 1.12 cm2 were exposed to either helium or 
control gas and grown in a CO2 incubator (Heracell 150 I CO2 incubator) at 37oC for 6, 12, or 
24 hours. FITC-BSA was diluted in water (25 mg FITC-BSA + 2.5 ml milliQ-water) and 
excessive exposure to light was avoided. After each time point 100 µl of FITC-BSA (10 mg/ml) 
was added to the upper compartment. After incubating for 2 hours at 37oC in a CO2 incubator, 
medium from the lower compartment was collected and stored at -80oC. Before permeability 
was measured a standard curve was prepared by diluting FITC-BSA in M2. Standards and 
samples were loaded in duplicates into a 96-well-plate (OptiPlate 96 Black) and read by a 
microplate fluorescence reader (FLx800) using KC4 software (BioTek). The concentration of 
FITC-BSA in the samples was calculated based on the FITC-BSA standard calibration curve.  
 
  
Figure 9: Set-up of the permeability assays 
Upper compartment
Lower compartment
Transwell insert
Microporous membrane
Confluent HUVEC	
monolayer
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2.2.6  Statistics 
 
For experiments evaluating the effect of helium/control gas on permeability and the expression 
of junctional molecules in Cav-1 siRNA transfected and non-transfected HUVEC, 7 or more 
independent experiments were performed. The exact number of independent experiments 
performed for each set of experiments is listed in the respective figure legend.  
Statistical analysis was performed using the statistics software program GraphPad Prism 7 for 
Windows (GraphPad Software, La Jolla, CA, USA). Cav-1 knock-down experiments (3.1) were 
analyzed using t-tests. All other data (3.2 and 3.3) were analyzed using a two way analysis of 
variance (ANOVA) for repeated measures with a Sidak’s multiple comparison test. Values of 
p<0.05 were considered statistically significant. Data are described as mean ± SD (standard 
deviation). 
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3.  Results 
3.1  Cell transfection and Cav-1 knock-down 
 
In order to investigate the role of Cav-1 in the helium-mediated changes of the endothelial 
permeability and the expression rates of VE-cadherin and Cx43, a knock-down model of the 
human endothelium was established. The transfection efficiency was evaluated by western 
blot analysis using cell lysates.  
HUVEC transfected with siRNA for Cav-1 contained significantly lower amounts of Cav-1 
compared to controls (34.82±20.07% vs. 100.00%, p<0.05, Fig. 10), which indicates 
successful Cav-1 knock-down.  
 
Figure 10: Cav-1 siRNA transfection efficiency in HUVEC 
Western blot results of the ratio of Cav-1 compared to 
GAPDH loading controls in HUVEC transfected with Cav-1 
siRNA and negative controls. Cav-1 protein expression is 
shown as percentage of the negative controls which were 
set at 100%. Representative western blot results are 
displayed below the respective graph. n=6 (6 independent 
experiments, 6-10 replicated in separate wells per 
experiment). Data are represented as mean±SD, * = 
p<0.05, Cav-1 = caveolin-1, GAPDH = Glyceraldehyde 3-
phosphate dehydrogenase, HUVEC = human umbilical vein 
endothelial cells.  
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3.2  Helium-induced attenuation of permeability of HUVEC  
       monolayers is dependent on Cav-1 
 
3.2.1  Effects of helium on permeability of non-transfected HUVEC  
 
The permeability of confluent HUVEC monolayers was measured at different time points after 
treatment with 20 min of helium or control gas.  
Helium treatment decreased cellular permeability in non-transfected HUVEC after 6 hours 
compared to controls (helium: 8.69±1.68 vs. control: 53.62±42.61, p<0.05; Fig. 11), and this 
effect remained present after 12 hours (helium: 17.86±8.31 vs. control: 67.96±36.95, p<0.05; 
Fig. 11), but not after 24 hours (p>0.05; Fig. 11). 
 
Figure 11: Effect of helium on permeability of 
non-transfected HUVEC 
Results of helium on permeability of a confluent 
monolayer of non-transfected HUVEC, estimated 
by the transfer of FITC-BSA at different time points 
compared to control gas. n=9 (7 independent 
experiments were performed by M. Landau, 
Laboratory of Experimental Intensive Care and 
Anesthesiology (L.E.I.C.A.), Amsterdam, while 2 
independent experiments were performed as part 
of this thesis). Data are represented as mean±SD, 
* = p<0.05, HUVEC = human umbilical vein 
endothelial cells. 
 
3.2.2  Effects of helium on permeability of Cav-1 siRNA transfected HUVEC 
 
In order to investigate if the barrier protective effect of helium is dependent on Cav-1, HUVEC 
were transfected with Cav-1 siRNA prior to helium application. The effect of helium on the 
permeability of Cav-1 knock-down HUVEC monolayers was measured at different time points 
after treatment with 20 min of helium or control gas. 
Cav-1 knock-down in HUVEC completely abolished the helium-mediated decrease in 
permeability described above and no significant differences between the helium and control 
group were detected (helium vs. control gas, all time points p>0.05; Fig. 12). 
0
FI
TC
	B
SA
	(µ
g/
m
l)
50
100
6																														12																													24	(h)
150
Control	gas
Helium
HUVEC
non-transfected
∗ ∗
Results 
 
 
 
32 
 
Figure 12: Effect of helium on permeability of 
Cav-1 siRNA transfected HUVEC 
Results of helium on permeability of a confluent 
monolayer of Cav-1 siRNA transfected HUVEC,  
estimated by the transfer of FITC-BSA at different 
time points compared to control gas. n=8 (8 
independent experiments). Data are represented 
as mean±SD, * = p<0.05, Cav-1 = caveolin-1, 
HUVEC = human umbilical vein endothelial cells. 
 
 
 
 
3.3  Helium increases VE-cadherin and Cx43 levels in HUVEC 
       possibly via Cav-1 
 
3.3.1  Effect of helium on VE-cadherin and Cx43 levels in non-transfected  
          HUVEC 
 
To reveal a possible molecular mechanism behind the helium-mediated decrease in 
permeability, the effect of helium on the expression rates of the junctional molecules VE-
cadherin and Cx43 was investigated. 
Helium treatment of HUVEC showed significantly increased cellular levels of VE-cadherin and 
Cx43 at 6 hours and 12 hours after treatment compared to treatment with control gas (VE-
cadherin in helium treated cells at 6 hours: 1.19±0.28 and 12 hours: 1.14±0.37. VE-cadherin 
in control cells at 6 hours: 0.87±0.11 and 12 hours: 0.85±0.14. Cx43 in helium treated cells at 
6 hours: 1.31±0.39 and 12 hours: 1.27±0.37. Cx43 in control cells at 6 hours: 0.90±0.32 and 
12 hours: 0.82±0.26. p<0.05 for all; Fig. 13 A and B). This effect subsided 24 hours after 
treatment (p>0.05; Fig. 13 A and B). 
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Figure 13: Effect of helium on VE-cadherin and Cx43 levels in non-transfected HUVEC 
Panel A: Western blot results of the ratio of VE-cadherin compared to GAPDH loading controls in non-
transfected HUVEC at different time points following helium or control gas treatment. n=14 (14 
independent experiments). Panel B: Western blot results of the ratio of Cx43 compared to alpha-tubulin 
loading controls in non-transfected HUVEC at different timepoints following helium or control gas 
treatment. n=11 (11 independent experiments).  
Representative western blot results are displayed below the respective graphs. Data are represented 
as mean±SD. * = p<0.05, Cx43 = connexin-43, GAPDH = Glyceraldehyde 3-phosphate dehydrogenase, 
HUVEC = human umbilical vein endothelial cells, VE-cadherin = vascular endothelial - cadherin.  
 
3.3.2  Effect of helium on VE-cadherin and Cx43 levels in Cav-1 siRNA  
          transfected HUVEC 
 
In order to investigate if the observed effect of helium on the junctional molecules VE-cadherin 
and Cx43 is related to Cav-1, HUVEC were transfected with Cav-1 siRNA, to knock down the 
Cav-1 expression prior to helium application. 
A knock-down of Cav-1 in HUVEC completely abolished the helium-mediated increase in the 
expression of the junctional molecules VE-cadherin and Cx43. Western blot analysis of VE-
cadherin and Cx43 showed no significant differences between the helium and control gas 
group at any timepoint (helium vs. control gas, all time points p>0.05; Fig. 14 A and B). 
Interestingly, Cx43 showed a time dependent decrease in protein expression independently of 
helium or control gas application (Fig. 14 B). 
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Figure 14: Effect of helium on VE-cadherin and Cx43 levels in Cav-1 siRNA transfected HUVEC 
Panel A: Western blot results of the ratio of VE-cadherin compared to GAPDH loading controls in Cav-
1 siRNA transfected HUVEC at different time points following helium or control gas treatment. n=7 (7 
independent experiments). Panel B: Western blot results of the ratio of Cx43 compared to alpha-tubulin 
loading controls in Cav-1 siRNA transfected HUVEC at different timepoints following helium or control 
gas treatment. n=7 (7 independent experiments). 
Representative western blot results are displayed below the respective graphs. Data are represented 
as mean±SD. * = p<0.05, Cx43 = connexin-43, GAPDH = Glyceraldehyde 3-phosphate dehydrogenase, 
HUVEC = human umbilical vein endothelial cells, VE-cadherin = vascular endothelial - cadherin.   
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3.4  Summary of results 
 
The results suggest that (i) helium decreases permeability of a confluent monolayer of HUVEC, 
(ii) helium increases VE-cadherin and Cx43 protein expression, and (iii) Cav-1 knock-down 
abrogates the effects of helium on permeability and VE-cadherin/Cx43 expression. 
Since VE-cadherin and Cx43 are known to regulate endothelial function (47,54,75), we 
hypothesize that the helium-induced decrease in endothelial permeability, is mediated by the 
observed changes in the expression rates of VE-cadherin and Cx43. 
 
  
Figure 15: Helium-mediated alteration of endothelial permeability: Involvement of Cav-1, VE-
cadherin and Cx43 
A: Helium attenuates permeability of HUVEC monolayers which is dependent on Cav-1. B: Helium 
increases Cx43 levels in HUVEC which is dependent on Cav-1. C: Helium increases VE-cadherin levels 
in HUVEC which is dependent on Cav-1. Cav-1 = caveolin-1, Cx43 = connexin-43, He = helium, VE-
cadherin = vascular endothelial - cadherin. Molecules pictured in red are investigated within this study.
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4.  Discussion 
4.1  Helium and organ protective strategies 
 
The non-anesthetic noble gas helium has gained high interest in organ protective strategies, 
because in contrast to volatile anesthetics, it can be used also in awake patients (24). 
Experimental studies in animals have shown that helium can mimic ischemic preconditioning 
and protect different organs including the heart (26–36), brain (37–42), liver (104) and intestine 
(105) from I/R-injury. 
Recent studies showed that helium is able to protect the heart against I/R-injury and to reduce 
infarct size (26–36). In 2007 Pagel et al. were the first who showed in animal experiments that 
helium can induce preconditioning of the heart (26). In their study the authors exposed rabbits 
to three times 5 min inhalation of 70% helium, each 5 min session separated by 5 min of air 
inhalation, followed by a coronary occlusion of the anterior descending coronary artery (LAD) 
for 30 min and 3 hours of reperfusion (26). Helium inhalation prior to the coronary artery 
occlusion significantly reduced the infarct size (26). Since this publication numerous studies 
by the same authors as well as others have been published, confirming the feasibility of helium-
induced conditioning in animal models (27–42,104,105). 
The protective effect of helium-induced conditioning on the brain is also well investigated in 
animal models (37–42). Pan et al. were the first to demonstrate the protective effect of helium-
induced conditioning on the brain in animals (40). Focal cerebral ischemia was induced 
through 2 hours of middle cerebral artery occlusion and 1 hour of reperfusion (40). During 
artery occlusion and reperfusion rats inhaled 70% helium (40). In this animal model of focal 
cerebral ischemia, helium treatment reduced infarct volume and improved 24 hour neurological 
outcome compared to the control group inhaling 30% O2/70% N2 gas mixture and compared 
to the normobaric hyperoxia group inhaling 100% O2 (40). 
In 2014 Zhang et al. revealed that helium preconditioning, furthermore, protects the liver from 
I/R-injury (104). Helium preconditioning was induced by inhalation of three times 5 min of 70% 
helium before a midline laparotomy and 90 min of occlusion of the structures left to the porta 
hepatis (hepatic artery, portal vein, and bile duct) in mice (104). The authors found that helium 
preconditioning significantly increased the actin phosphorylation in hepatocytes and resulted 
in attenuated hepatocellular injury and increased survival in the treated animals (104). 
A more recent trial, published in 2015, demonstrated that helium preconditioning in animals 
also protects the intestine from I/R-injury (105). Rats were treated with three times 5 min of 
70% helium inhalation before 60 min of intestinal I/R induced by superior mesenteric artery 
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occlusion and 60 min of reperfusion (105). Helium preconditioning reduced the I/R-induced 
increase in intestinal permeability, cell apoptosis and the inflammatory response (105).  
The large amount of experimental data on helium-induced conditioning has so far not been 
translated to the clinical situation (23). However, a study by Smit et al. demonstrated that 
helium protects the human endothelium from I/R-injury by mimicking the early and late events 
of ischemic preconditioning (21). Healthy human volunteers were treated with 79% helium 
directly before or 24 hours before forearm ischemia and reperfusion induced by an inflated 
blood pressure cuff on the forearm for 20 min (21). Endothelial dysfunction was evaluated by 
measuring the blood flow in the forearm in response to infusion of acetylcholine before and 
after 20 min of I/R (21). In this study early and late preconditioning by helium inhalation 
successfully attenuated the endothelial dysfunction induced by I/R and thereby, mimicked the 
effect of ischemic preconditioning (21). 
A following study by Smit et al. was intended to translate the protective effect of helium into 
the clinical setting (106). In this first clinical trial the effect of helium was evaluated in patients 
subjected to coronary artery bypass graft surgery (106). Patients inhaled 3 x 5 min of 79% 
helium before the start of cardiopulmonary bypass or at the timepoint of coronary artery 
reperfusion (106). Surprisingly, no effect of helium preconditioning, postconditioning, or a 
combination of both was seen in signal transduction kinases or postoperative troponin release 
(106). Therefore, further clinical studies are necessary to evaluate the feasibility of pre- and 
postconditiong by helium in this and other clinical situations.  
 
4.2  HUVEC as an in-vitro model for the human endothelium 
 
To investigate the cellular and molecular mechanisms responsible for the barrier protective 
effects of helium, HUVEC monolayers were used as a model of the human endothelium. This 
cell culture model is widely used in preclinical research (107–111). 
HUVEC are non-immortalized human cells and isolation without contamination of other cell 
types is comparatively simple to conduct (112). Human umbilical cords are resected after 
delivery, making human umbilical veins easy to obtain (112). HUVEC monolayers have been 
used in cell research for several decades. In 1963 Maruyama et al. were the fist who published 
the successful isolation of HUVEC (107). The authors cannulated the umbilical vein after post-
natal resection of the umbilical cords and detached HUVEC utilizing trypsin (107). By the time 
HUVEC are properly differentiated they obtain the so-called cobblestone phenotype (112). In 
this stage they mimic an endothelium in-vivo and can be utilized to study endothelial-related 
processes (112).  
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In the course of the present study, permeability for albumin was assessed for HUVEC 
monolayers after treatment with helium or a control gas. HUVEC were seeded on a 
microporous membrane with a pore diameter size of 0.4 µm; permeability was assessed by 
FITC-BSA flow-throw in 2 hours. The described protocol used to assess permeability was 
already established in our laboratory and was initially developed based on Kiemer et al., with 
some modifications (113). In the study by Kiemer et al., as well as in the present study, FITC-
BSA flow-through was applied to assess permeability (113). The use of different forms of 
labeled albumin to assess endothelial permeability of HUVEC monolayers was described in 
several publications (84,111,113–120). However, fluorescence-labeled dextrans are also 
frequently used as molecular tracers to assess permeability of HUVEC monolayers (111,121–
127). The passage of dextrans occurs only by passive diffusion through the inter-cellular clefts, 
albumin however, passages by a combination of active vesicular transport and para-cellular 
transport (111). Since vascular leakage of plasma albumin is one of the consequences of I/R-
injury (128), albumin flow-through was selected to assess HUVEC monolayer permeability 
within this study. 
In order to investigate whether Cav-1 is involved in the helium-mediated stabilization of the 
endothelial barrier function, a Cav-1 knock-down model, using siRNA transfection in HUVEC, 
was established. The relatively low proliferative rate and limited lifespan of HUVEC make it 
more challenging to transfect them compared to immortalized cell lines (129). However, these 
characteristics imply that HUVEC may reflect the in-vivo situation of the endothelium better 
than immortalized cell lines (129). 
After transfection, siRNA forms RNA-induced silencing complexes inside the cell, which block 
the expression of a target gene expression (130). Transfection can be achieved by biological, 
physical or chemical methods (130). Biological methods are virus-mediated and also known 
as transduction, whereas physical methods employ various physical instruments to transport 
nucleic acids across the cell membrane into the cytoplasm or nucleus (130). Chemical 
methods employ positively charged transfection reagents (cationic polymers, calcium 
phosphate, cationic lipids, or cationic amino acids) for the transport across the cell membrane 
(130). The positively charged transfection reagents form complexes with the negatively 
charged siRNA, building positively charged siRNA/transfection reagent complexes that are 
attracted to the negatively charged cell membrane (130). Endocytosis and phagocytosis are 
presumably involved in the passage of the siRNA/transfection reagent complexes through the 
cell membrane (130). However, the exact mechanism of the passage is unknown (130). 
Transfections of Cav-1 siRNA into HUVEC by means of chemical methods has been described 
in various publications (84,95–101) and was, therefore, also employed in the present study. 
Sun et al. have employed Lipofectamine RNAiMAX to transfect HUVEC with Cav-1 siRNA (95); 
the same transfection reagent was employed in the present study. The authors investigated 
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the underlying mechanism of endothelial dysfunction caused by atheroprone (oscillatory) flow 
compared to atheroprotective (pulsatile) flow (95). Proteins in HUVEC exposed to atheroprone 
flow were analyzed and integrin alpha5 was the most significantly elevated protein in lipid rafts 
(95). Remarkably, a Cav-1 knock-down by siRNA transfection abrogated the integrin alpha5 
translocation and activation induced by atheroprone flow (95). A preceding study employing 
Cav-1 siRNA transfection of HUVEC, investigated the role of Cav-1 in insulin and insulin-like 
growth factor 1 stimulated eNOS activity (100). A Cav-1 knock-down in HUVEC abrogated the 
insulin and insulin-like growth factor 1-induced eNOS phosphorylation (100).  
In the present study protein levels of Cav-1 were reduced to 34.82% in Cav-1 siRNA 
transfected HUVEC compared to negative controls, indicating successful Cav-1 knock-down. 
Other publications reported Cav-1 levels remaining in a range between 10% and 33% after 
Cav-1 siRNA transfection: 10% Salani et al. (101), 19.8% Jiang et al. (84), 20% Beardsley et 
al. (99), 20% Repetto et al. (100), less than 33% van der Meer et al. (98). 
The implementation of a permeability model in Cav-1 siRNA transfected endothelial cells was 
described by Liu et al. as well as Jiang et al. (84,131). Jiang et al. assessed permeability for 
albumin of monolayers formed by transfected HUVEC (84), while in the study by Liu et al. 
mouse brain microvascular endothelial cells were transfected and permeability was assessed 
by dextran flow-through (131). Further details about these studies will be given below. 
 
4.3  Effects of helium on endothelial barrier function 
 
Previous experiments of our laboratory showed that helium treatment regulates the Cav-1/3 
expressions in mice hearts (67). Within this study mice inhaled 70% helium which led to 
decreased levels of Cav-1/3 in the heart after 24 hours, while elevated levels were found in 
the serum of the animals (67). These findings led to the hypothesis that Cavs are secreted into 
the blood stream after helium inhalation. Increased amounts of Cav-3 in the serum after helium 
inhalation were confirmed in rats in a recent study by Flick et al. (83). However, the analysis 
of the membrane fraction of the area at risk in the study by Flick et al. showed increased levels 
of Cav-1/3 after helium inhalation which somehow contrasts  with the findings in mice, where 
helium led to decreased levels of Cav-1/3 in hearts (67). 
As the endothelium is the first target organ to get in contact with circulating blood, a following 
study of our laboratory translated the recent findings to the human endothelium. Within this 
study the effect of helium on the human endothelium was investigated in-vitro. Results for Cav-
1 levels were in line with the findings in mice and showed that helium leads to decreased intra-
cellular protein levels of Cav-1 and elevated extra-cellular levels (43). These findings 
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supported the hypothesis that Cav-1 might be released by the stimulus of helium. A 
translocation of Cav-1 in endothelial cells was also described for mouse brain microvascular 
endothelial cells (131). However, in these cells deprivation of oxygen and glucose led to a 
translocation of Cav-1 from the cytoskeleton to the cytosol (131). Even though this study did 
not show a translocation to the extra-cellular space, as shown for helium treatment, the findings 
still support the concept that different stimuli might translocate endothelial Cav-1. 
  
Earlier findings of our laboratory (43) and a repetition of these experiments within this study 
showed decreased endothelial permeability for albumin after helium treatment, which is an 
indicator for improved endothelial barrier function (43). Since ischemia and reperfusion leads 
to a weakened barrier function of the endothelium and can result in increased vascular 
permeability and vascular leakage (6,12,13,128), the protective effect of helium treatment on 
the endothelium might be a key mechanism of organ protection by helium.  
There is inconsistent experimental data regarding the effect of helium on endothelial function. 
An in-vivo study by Lunchinetti et al. contrasts with our findings by not showing endothelial 
protection after helium inhalation in humans (132). Eight healthy male volunteers were 
exposed to 15 min of forearm I/R in a cross-over study design (132). Combined pre- and 
postconditioning by helium was applied by inhalation of 50% helium from 15 min before 
ischemia until 5 min after onset of reperfusion (132). Hyperemic reaction, assessed by venous 
occlusion plethysmography, was used as a marker of nitric oxide bioavailability and endothelial 
function (132). However, in this study the concentration of helium (50%) was relatively low 
compared to other studies and it cannot be ruled out that inhalation of helium in a concentration 
of 70% or higher might have provided endothelial protection (132). In the study by Smit et al. 
that demonstrated a protective effect of helium preconditioning on the human endothelium in-
vivo, helium was inhaled in a considerably higher concentration of 79% (21). A further study 
by Du et al. demonstrated that preconditioning with 70% helium inhalation attenuated intestinal 
permeability after I/R in animals in-vivo (105), indicating a barrier protective effect of helium. 
However, this study evaluated the effect of helium on intestinal permeability and can, therefore, 
not be directly transferred to the endothelium. 
The mean permeability of non-transfected, control gas treated HUVEC monolayers, assessed 
by FITC-BSA flow-through in 2 hours, was lower at 24 hours compared to 6 and 12 hours. 
These findings might be explained by the experimental set-up. As described in the methods 
section, the different timepoints (6, 12 and 24 hours) refer to the time span between helium or 
control gas treatment and the onset of assessing monolayer permeability by FITC-BSA flow-
through in 2 hours. HUVEC monolayers used at the 24 hour timepoint were cultured on the 
microporous membranes for 18 hours longer compared to HUVEC monolayers used at the 6 
hour timepoint and for 12 hours longer compared to HUVEC monolayers used at the 12 hour 
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timepoint. This might have led to a higher confluency and, thereby, less inter-endothelial space 
of the HUVEC monolayer, resulting in decreased FITC-BSA flow-through. However, this 
assumption does not explain why the permeability of Cav-1 siRNA transfected HUVEC 
monolayers increases over time independently of helium or control gas treatment. SiRNA 
transfection is cytotoxic and leads to cell death in HUVEC (133). This cytotoxicity might have 
led to increasing inter-endothelial gaps and therefore increasing FITC-BSA flow-through over 
time in Cav-1 siRNA transfected HUVEC monolayer. 
 
In order to investigate whether Cav-1 is involved in the helium-mediated stabilization of the 
endothelial barrier, Cav-1 protein levels were significantly reduced by siRNA transfection. 
Utilizing a Cav-1 knock-down model, we showed that reduced protein levels of Cav-1 
abrogated the protective effect of helium on the endothelial barrier function. These findings 
suggest a key role of Cav-1 in the pathway that finally leads to a decreased endothelial 
permeability after helium treatment.  
The role of Cavs in anesthetic-induced organ protection is well described (68,82,86). Reports 
have shown that the Cav isoforms Cav-1 and 3 are critically involved in pharmacological 
conditioning by volatile anesthetics (68,82,86). Patel et al. have demonstrated that infarct size 
reduction induced by isoflurane preconditioning was abrogated in Cav-1-null mice (82). 
Experiments in Cav-3-null mice revealed that also the absence of Cav-3 abrogated the 
protective effect of the volatile anesthetic isoflurane on the infarct size reduction and, 
furthermore, abrogated the protective effect on troponin release (68). A similar study, published 
in 2015, recently confirmed the abrogation of the protective isoflurane effect in Cav-3 knock-
out mice and additionally showed in wild type mice that pharmacological preconditioning with 
isoflurane led to increased Cav-3 levels in the mice hearts (86). These findings suggest a key 
role of Cavs in anesthetic-induced conditioning. The main difference between the present 
study and the mentioned preconditioning studies is that in the present study no ischemia model 
was applied and that purely the effect of helium on the endothelium was investigated.  
Jiang et al. have recently shown that hypoxic trophoblast conditioned medium increased Cav-
1 protein levels as well as the permeability for albumin of HUVEC monolayers (84). In the 
mentioned report, high cellular protein levels of Cav-1 were associated with high permeability 
for albumin (84). This correlation between Cav-1 levels and HUVEC permeability matches the 
findings of our laboratory that helium leads to decreased intra-cellular protein levels of Cav-1 
and a decreased permeability for albumin of HUVEC monolayers (43). Jiang et al. have, 
furthermore, found that the increase in permeability induced by hypoxic trophoblast 
conditioned medium was abrogated by a Cav-1 knock-down in endothelial cells (84). These 
results are once more in line with our results, revealing that the helium-induced attenuation of 
permeability of HUVEC monolayers is abrogated by a Cav-1 knock-down.  
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In mouse brain microvascular endothelial cells deprivation of oxygen and glucose led to an 
increase in dextran flow-through measured after 2 hours, indicating a disruption of the 
endothelial barrier function (131). A Cav-1 knock-down by siRNA significantly reduced the 
permeability of the endothelial monolayer treated with a deprivation of oxygen and glucose 
(131), indicating that Cav-1 is also involved in regulating endothelial barrier function in 
response to other stimuli than helium. The same study further revealed that the TJ protein 
claudin-5 is regulated by an interaction with Cav-1 (131). Deprivation of oxygen and glucose 
in endothelial cells led to increased protein levels of claudin-5 in the cytosolic, membrane and 
organelle fraction and a decrease in the levels in the actin cytoskeleton fraction (131). This 
dissociation of claudin-5 from the cytosolic framework was abrogated in Cav-1 siRNA 
transfected cells (131). These findings of Liu et al. demonstrated that Cav-1 is involved in the 
regulation of the TJ protein claudin-5 in endothelial cells (131). However, the mentioned study 
was performed using a different endothelial cell line and a different treatment was applied 
compared to the present study. Nevertheless, by demonstrating the association of Cav-1 to 
the regulation of a protein of the inter-endothelial junction, this study points in the same 
direction as the present study.  
 
Western blot analyses revealed that 20 min of helium treatment led to significantly elevated 
protein levels of VE-cadherin and Cx43 in HUVEC and a Cav-1 protein knock-down completely 
abrogated this effect. 
VE-cadherin, the main molecule to form AJ, is essential in maintaining endothelial barrier 
function (47,54). Recent studies have shown that VE-cadherin is also involved in 
pharmacological conditioning: Anesthetic-induced preconditioning by sevoflurane preserves 
endothelial barrier dysfunction by maintaining VE-cadherin levels (72), angiopoietin-1 
preserves vascular leakage through a regulation of VE-cadherin phosphorylation (73) and the 
herbal medicine extract tongxinluo, which is also known to induce preconditioning, leads to an 
upregulation of VE-cadherin (74).  
Cx43, the protein forming GJ, enables inter-cellular communication in endothelial cells and, 
thereby, regulates vascular tone and endothelial function (75). Alterations in the Cx43 levels 
are associated with myocardial diseases such as heart failure, hypertrophic cardiomyopathy 
and ischemia (75). Cx43 is critically involved in ischemic preconditioning of the heart 
(87,134,135) and experiments have shown that the organ protecting effect of ischemic 
preconditioning was abrogated in Cx43 deficient mice (87) as well as after using the 
pharmacological GJ uncoupler heptanol (134). Furthermore, augmented levels of Cx43 were 
found in ischemically preconditioned rabbit hearts (135).  
As the mentioned pharmacological and ischemic conditioning agents lead to elevated levels 
of VE-cadherin and/or Cx43, these findings are in line with our finding that helium leads to 
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augmented protein levels of VE-cadherin and Cx43 in the endothelium. Since VE-cadherin 
maintains endothelial barrier function (47,54,136) and Cx43 is known to modulate endothelial 
function (75), the increased levels of these junctional molecules could be involved in the 
underlying mechanism of helium-mediated attenuation of the endothelial barrier function.  
Findings of a study investigating the effect of the ginkgo leaf extract ginkgolide B in HUVEC, 
stand in contrast to our findings (137). This study showed that ginkgolide B leads to decreased 
expressions of the junctional molecules VE-cadherin and Cx43 and decreased monocyte 
transmigrations, indicating enhanced endothelial barrier function (137). The same study further 
showed decreased monocyte migrations after knock-down of VE-cadherin and Cx43 by 
siRNA. Experiments of our laboratory, however, showed that helium leads to a decreased 
permeability of the endothelium (43) and increased protein levels of VE-cadherin and Cx43 
after helium treatment. The contrary correlation between the VE-cadherin or Cx43 levels and 
endothelial permeability might be explained by the different experimental set-ups used to 
assess permeability. In the studies performed in our laboratory, permeability was measured 
by albumin flow-through in 2 hours (43), whereas in the study testing the effect of ginkgolide 
B, a monocyte flow-through in 24 hours was used to evaluate permeability (137). Monocytes 
can actively secrete proteases and thereby have a direct influence on cell-cell adhesions (138). 
The active secretion of proteases, the difference in the size of FITC-BSA and monocytes as 
well as the difference in the timespan (2 hours for FITC-BSA vs. 24 hours for monocytes) might 
explain the deviating findings.  
 
We demonstrated that Cav-1 plays a possible role in helium-mediated attenuation of 
endothelial permeability and since an interaction of Cav-1 with VE-cadherin (139,140) and 
Cx43 (79,141–144) has been described in literature, this prompted us to investigate whether 
Cav-1 is also involved in the helium-induced increase of the protein levels of VE-cadherin and 
Cx43.  
Our results showed that helium significantly increased the VE-cadherin and Cx43 levels in wild 
type HUVEC. However, this effect was completely abrogated in a Cav-1 knock-down model of 
the endothelium. These findings enabled us to conclude that Cav-1 is essential in mediating 
the helium-induced alterations in the junctional molecules VE-cadherin and Cx43, which might 
finally lead to a decreased vascular permeability.  
A study by Kronstein et al. supports our results, showing that Cav-1 plays a key role in VE-
cadherin dependent cell adhesion and the regulation of the barrier function (139). The authors 
determined that Cav-1 forms complexes with VE-cadherin and catenin in HUVEC and 
demonstrated that this association is essential for the decreased barrier function in response 
to the pro-inflammatory mediator thrombin (139). Our findings are further supported by the 
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findings that Cx43 binds to the scaffolding domain of caveolin (CSD) and might, therefore, be 
regulated by Cav-1 (79).  
Interestingly, in Cav-1 siRNA transfected HUVEC we found a time dependent decrease in 
protein levels of Cx43 independently of helium or control gas treatment. To our knowledge this 
time dependent decrease of the Cx43 protein levels in Cav-1 siRNA transfected HUVEC has 
not been described before. Cx43 has a relatively short half-life of a few hours (145), most likely 
to enable a regulation of the number of GJs in response to physiological requirements (146). 
Since Cx43 is regulated by Cav-1 (79,142), the time dependent decrease in the protein levels 
of Cx43 might be explained by lower rates of protein synthesis in absence of Cav-1. This in 
combination with the relatively short half-life of Cx43 could lead to a time dependent decrease 
of the protein levels of Cx43 in Cav-1 knock-down cells. Langlois et al. have transfected rat 
epidermal keratinocytes with Cav-1 siRNA to reduce Cav-1 protein levels; the expression of 
Cx43 were not affected by the Cav-1 knock-down (142). However, the authors did not assess 
Cx43 protein levels at different timepoints. Therefore, a time dependent decrease could not be 
ruled out. 
 
Taken together, our results in combination with current literature suggest that helium 
attenuates endothelial permeability by increasing protein levels of VE-cadherin and Cx43, 
most likely through an interaction with Cav-1.  
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4.4  Limitations of the study 
 
There are several limitations of this study that need to be considered: 
(i) This study was performed using an in-vitro model of the human endothelium. Therefore, the 
results cannot be directly transferred to the in-vivo situation. For a possible translation of this 
data to a clinical setting, further in-vivo research is necessary.  
(ii) No flow or shear stress was applied to endothelial cells in the present study. It is known 
that endothelial cells are sensitive to flow and shear stress and caveolae are known to sense 
flow, shear stress and stretch and control membrane tension (98,147,148). Therefore, it cannot 
be excluded that the absence of flow, shear stress and stretch has influenced the results.  
(iii) In the present study siRNA was used to accomplish a functional knock-down of Cav-1. This 
technique was used in HUVEC in various publications (84,95–101). However, there are some 
limitations to this technique. Although siRNA for Cav-1 was used to induce a post-
transcriptional gene silencing, the Cav-1 protein was not completely absent: in the present 
study 34.82% of the protein levels were shown to remain in the cell and might have influenced 
the results.  
(iv) It cannot be excluded that off-target effects of the siRNA have influenced the results. 
Furthermore, the use of a transfection reagent (133) or “serum starving” prior to the 
transfection might have influenced the results.  
(v) The final objective of the present study in combination with previous and future studies is 
the use of helium to prevent organs from the I/R-injury in various clinical settings. In the present 
study, however, only the effect of helium on the human endothelium was investigated and no 
damage model was applied to induce an I/R-injury. Further in-vitro and in-vivo studies have to 
reveal whether helium pre- and postconditioning is potent enough to maintain the endothelial 
barrier function after an I/R-injury.  
 
4.5  Conclusion 
 
Our findings suggest that Cav-1 is involved in (i) the helium-mediated attenuation of 
permeability of HUVEC monolayers and in (ii) the helium-mediated increase in protein 
expression of the junctional molecules VE-cadherin and Cx43.  
This study in combination with further translational trials could help to implement helium into 
organ protective strategies in humans.   
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4.6  Further perspectives 
 
There are numerous clinical situations of ischemia and reperfusion in which patients could 
profit from pre- or postconditioning by the non-anesthetic noble gas helium. Possible clinical 
applications of helium preconditioning are predictable events of ischemia and reperfusion, 
including situations like heart-, vascular- or transplantation surgery. Possible clinical 
applications for helium postconditioning include more unpredictable events like infarctions of 
the coronaries (acute myocardial infarction, AMI), infarctions of intestinal blood vessels (acute 
mesenteric ischemia) or any other type of arterial occlusion (e.g. acute peripheral arterial 
occlusion). 
 
Based on the results of this study further scientific questions arose: 
(i) Results of the present study revealed that helium attenuates permeability of HUVEC 
monolayers possibly via Cav-1. Since the final perspective is the use of helium to protect 
organs in various clinical I/R situation, further animal experiments should be performed in 
combination with the application of an ischemia model. 
(ii) Since helium leads to decreased intra-cellular protein levels of Cav-1 and elevated extra-
cellular levels as well as a strengthened endothelial barrier function that is abrogated in a Cav-
1 knock-down model, further studies should investigate whether externally added Cav-1 can 
mimic the protective effect of helium on the endothelial barrier function. 
(iii) In the present study a Cav-1 knock-down model in HUVEC was used. Further experiments 
have to reveal in what way a knock-down of other proteins like eNOS, also known to be 
involved in helium-induced organ protection (32), would affect the helium-induced attenuation 
of permeability of HUVEC monolayers. 
(iv) Patients who could profit from the protective effects of helium conditioning in a clinical 
setting are patients undergoing coronary artery bypass graft surgery for example (21). These 
patients, however, are often of advanced age and have comorbidities, such as hypertension, 
diabetes mellitus and atherosclerosis (149). Therefore, further studies in cell models, animal 
models and humans are needed to investigate the protective effect of helium on the 
endothelium also in combination with an advanced age and comorbidities. 
 
Summary 
 
 
 
47 
5.  Summary 
 
Background: 
Protective effects of ischemic conditioning on the heart have been described in numerous 
publications. Recent studies suggested that the noble gas helium is also able to protect the 
heart against ischemia/reperfusion injury (I/R-injury). Mechanistically, helium can mimic the 
early and late effects of ischemic preconditioning and as helium lacks anesthetic and other 
side effects, it might be a potential conditioning agent. We have recently shown that (i) helium 
attenuates the permeability of monolayers of human umbilical vein endothelial cells (HUVEC) 
and that (ii) helium leads to decreased intra-cellular protein levels of caveolin-1 (Cav-1). 
Nevertheless, the underlying cellular and molecular mechanisms and the precise role of Cav-
1 in helium-mediated regulation of endothelial barrier integrity are still unclear. Employing in-
vitro cultured primary HUVEC and small interfering RNA (siRNA) transfection experiments, we 
therefore investigated (i) whether Cav-1 is involved in helium-mediated stabilization of the 
endothelial barrier and (ii) whether the expression of the key junctional molecules vascular 
endothelial - cadherin (VE-cadherin) and connexin-43 (Cx43) is regulated by helium and might 
be involved in the effects of helium on endothelial barrier function. 
 
Methods: 
HUVEC were obtained from umbilical cords, pooled and grown to confluency. Cells were either 
exposed to 20 min of helium (5% CO2, 25% O2, 70% He) or control gas (5% CO2, 25% O2, 
70% N2) in a specialized gas chamber. Permeability was measured using confluent 
monolayers of HUVEC on microporous membranes and fluorescein isothiocyanate labelled 
bovine serum albumin (FITC-BSA). To investigate if the effects of helium on the endothelial 
barrier function are related to Cav-1, HUVEC were transfected with Cav-1 siRNA prior to 
helium application in order to knock down the Cav-1 expression. Expression of VE-cadherin 
and Cx43 was analyzed by western blotting in non-transfected and Cav-1 siRNA transfected 
HUVEC.  
 
Results: 
HUVEC transfected with siRNA for Cav-1 showed significantly lower amounts of Cav-1 protein 
compared to controls (34.82±20.07% vs. 100.00%, p<0.05), confirming successful knock-
down of Cav-1.  
While helium attenuated the permeability of HUVEC monolayers in non-transfected HUVEC 
(p<0.05), effects of helium on cell permeability were abrogated in Cav-1 siRNA transfected 
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HUVEC (p>0.05), suggesting a key role of Cav-1 in endothelial permeability. In the helium 
group, protein analyses in cell lysates showed a significantly higher expression of VE-cadherin 
and Cx43 at 6 and 12 hours (VE-cadherin in helium treated cells at 6h: 1.19±0.28 and 12h: 
1.14±0.37. VE-cadherin in control cells at 6h: 0.87±0.11 and 12h: 0.85±0.14. Cx43 in helium 
treated cells at 6h: 1.31±0.39 and 12h: 1.27±0.37. Cx43 in control cells at 6h: 0.90±0.32 and 
12h: 0.82±0.26. Helium 6h and 12h vs. control 6h and 12h: p<0.05 for all groups). Transfecting 
HUVEC with Cav-1 siRNA abolished the effect of helium on VE-cadherin and Cx43 expression 
(p>0.05 for all time points), pointing towards a role of Cav-1 in the helium-induced alteration of 
junctional molecule expression. 
 
Conclusion: 
Our findings suggest that Cav-1 is involved in (i) the helium-mediated attenuation of HUVEC 
permeability and in (ii) the helium-mediated increase in the expression of the junctional 
molecules VE-cadherin and Cx43. This study in combination with further translational trials 
could help to implement helium into organ protective strategies in humans. 
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7.  Appendix 
7.1  List of manufacturers 
 
Abcam, UK; www.abcam.com 
Ambion, Germany; www.thermofisher.com 
Appli-Chem, Germany; www.applichem.com 
BD Diagnostic system, USA; www.bdbiosciences.com 
Bio-Rad, USA; www.bio-rad.com 
BioTek, USA; www.biotek.com 
BioTek Instruments, USA; www.biotek.com 
Cell Signaling Technology, USA; www.cellsignal.com 
Corning Costar, USA; www.corning.com 
Corning Life sciences, USA; www.corning.com 
Datex, USA; www.dremed.com 
Eppendorf, Germany; www.eppendorf.com 
Fisher Scientific, USA; www.fishersci.com 
Greiner Bio One, Austria; www.greinerbioone.com 
Invitrogen, USA; www.lifetechnologies.com 
Leica Microsystems, Germany; www.leica-microsystems.com 
LI-COR Biosciences, The Netherlands; www.westburg.eu 
Life technologies, USA; www.thermofisher.com 
Linde Gas Benelux, The Netherlands; www.linde-gas.nl 
Merck, Germany; www.merck.de 
MERCK Millipore, Germany; www.merckmillipore.de 
MFG by Henry Troemner, USA; www.troemner.com 
PAA, Germany; www.gelifesciences.com 
Packard BioScience, USA; www.packardbioscience.com 
PAN, Germany; www.pan-biotech.com 
Promocell, Germany; www.promocell.com 
Roche, Switzerland; www.roche-diagnostics.ch 
Sigma-Aldrich, The Netherlands; www.sigmaaldrich.com 
Telstar Laboratory Equipment, The Netherlands; www.telstar-lifesciences.com 
Thermo Scientific, USA; www.thermoscientific.com 
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7.2  Molecular formulas 
 
C2H6OS 2-Sulfanylethan-1-ol (2-Mercaptoethanol) 
C7H15NO4S 3-(N-morpholino)propanesulfonic acid (MOPS) 
CaCl2 Calcium chloride  
CO2 Carbon dioxide 
CuSO4 x H2O Copper(II) sulfate 
He Helium 
KH2PO4 Potassium dihydroxidodioxidophosphate 
KNaC4H4O6 x 4H2O KNa-Tartrate 
MgCl2 Magnesium chloride 
N2 Nitrogen 
Na2CO3  Sodium carbonate 
Na2HPO4 Sodium hydrogen phosphate 
Na3VO4 Sodium vanadate 
NaCl Sodium chloride 
NaOH Sodium hydroxide 
O2 Oxygen 
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